Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Calcagno

Showing results (11-20 of 258) with videos related to

Pageof 26
Sort By:
Infection|January 11, 2020
I have got you under my skinTommaso Lupia, Silvia Scabini, Giacomo Stroffolini, et al.
Therapeutic Drug Monitoring|September 3, 2025
Pharmacogenetics of First-Line Antitubercular Drugs: An UpdateAlessandra Manca, Andrea Calcagno, Antonio D'Avolio, et al.
Clinical Pharmacokinetics|September 20, 2016
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral DrugsAndrea Calcagno, Jessica Cusato, Antonio D'Avolio, et al.
Current HIV/AIDS Reports|January 25, 2018
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to ChooseAndrea Calcagno, Ambra Barco, Mattia Trunfio, et al.
The Lancet. Infectious Diseases|April 17, 2021
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary casesMattia Trunfio, Andrea Calcagno, Stefano Bonora, et al.
Expert Review of Clinical Pharmacology|December 5, 2018
The clinical pharmacology of integrase inhibitorsGiovanni Di Perri, Andrea Calcagno, Alice Trentalange, et al.
Journal of Hepatology|May 28, 2013
Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?Antonio D'Avolio, Jessica Cusato, Andrea Calcagno, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2020
JC virus DNA in cerebrospinal fluid: insight into clinical significanceSimone Mornese Pinna, Mattia Trunfio, Daniele Imperiale, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2013
Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid"Andrea Calcagno, Antonio D'Avolio, Giovanni Di Perri, et al.
AIDS (London, England)|May 30, 2024
Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIVMattia Trunfio, Stefano Bonora, Giovanni di Perri, et al.
Pageof 26

Showing results (11-20 of 258) with videos related to

Sort By:
Pageof 26
Infection|January 11, 2020
I have got you under my skinTommaso Lupia, Silvia Scabini, Giacomo Stroffolini, et al.
Therapeutic Drug Monitoring|September 3, 2025
Pharmacogenetics of First-Line Antitubercular Drugs: An UpdateAlessandra Manca, Andrea Calcagno, Antonio D'Avolio, et al.
Clinical Pharmacokinetics|September 20, 2016
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral DrugsAndrea Calcagno, Jessica Cusato, Antonio D'Avolio, et al.
Current HIV/AIDS Reports|January 25, 2018
CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to ChooseAndrea Calcagno, Ambra Barco, Mattia Trunfio, et al.
The Lancet. Infectious Diseases|April 17, 2021
Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary casesMattia Trunfio, Andrea Calcagno, Stefano Bonora, et al.
Expert Review of Clinical Pharmacology|December 5, 2018
The clinical pharmacology of integrase inhibitorsGiovanni Di Perri, Andrea Calcagno, Alice Trentalange, et al.
Journal of Hepatology|May 28, 2013
Estimating ribavirin plasma exposure: genetics or therapeutic drug monitoring?Antonio D'Avolio, Jessica Cusato, Andrea Calcagno, et al.
Diagnostic Microbiology and Infectious Disease|March 24, 2020
JC virus DNA in cerebrospinal fluid: insight into clinical significanceSimone Mornese Pinna, Mattia Trunfio, Daniele Imperiale, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2013
Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid"Andrea Calcagno, Antonio D'Avolio, Giovanni Di Perri, et al.
AIDS (London, England)|May 30, 2024
Further considerations on the use of cerebrospinal fluid C-X-C motif chemokine ligand 13 in the diagnosis of neurosyphilis among people with HIVMattia Trunfio, Stefano Bonora, Giovanni di Perri, et al.
Pageof 26